|Articles|August 15, 2013

Not a Risk Factor for Clostridium difficile Infection?

Previous antibiotic use and hospitalization are well known risk factors for C difficile infection. Are age, PPI use, immunosuppression, and BMI all also risk factors?

Previous antibiotic use and hospitalization are well known risk factors for the development of Clostridium difficile infection. All of the following are additional risk factors except which one?

A. Age
B. PPI use
C. Immunosuppression
D. BMI

Please click here for the answer and discussion.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Not a Risk Factor for Clostridium difficile Infection?

Related Content

OSA Treatment Beyond CPAP: Tirzepatide, Phenotyping, and What's Next, With Ashesha Mechineni, MD

GLP-1 Insurance Barriers Are Reshaping OSA Diagnostic Referral Patterns

Retatrutide Phase 3 Data Show Weight, A1C Reductions in Obesity and Type 2 Diabetes

Survey Finds Gaps in US Adult Awareness of HPV, Mpox STI Vaccine Prevention

FDA Approves Ensitrelvir as First Oral COVID-19 Postexposure Prophylaxis Option

Latest CME

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Wisconsin Association of Hematology and Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rhode Island Oncology Society

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

South Carolina Oncology Society

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

20th Annual New York Lung Cancers Symposium®

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

ISGIO 2025: Esophageal and Gastric Cancer

ISGIO 2025: Hepatobiliary Cancers

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Optimizing Multidisciplinary Care in TGCT

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

North Carolina Oncology Association

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)